Baxter Reports Q3 2026 Results, Raises FY26 Guidance, and Declares Dividend

Executive Summary

Baxter International Inc. filed a Form 8-K reporting its third-quarter 2026 financial results (Item 2.02) and announcing a quarterly cash dividend (Item 8.01).

Key Financial Highlights

• Worldwide Net Sales: $2.976 billion, up 5% year-over-year on both a reported and organic basis (vs. $2.835 billion in Q3 2025).
  • U.S. Sales: ~$1.6 billion (+3% reported, +5% organic).
  • International Sales: ~$1.4 billion (+7% reported, +6% organic).
• Profitability:
  • U.S. GAAP Net Income: $298 million, or $0.57 per diluted share.
  • Adjusted Diluted EPS: $0.58, down 16% YoY primarily driven by a higher effective tax rate.
  • Operating Income: $225 million (7.6% of sales) vs. $172 million (6.1% of sales) in Q3 2025 (+31% YoY).
• Cash Flow & Capital Structure:
  • Free Cash Flow: $448 million in Q3 2026; $705 million year-to-date.
  • Debt Reduction: Completed a $600 million cash tender offer in Q3, successfully retiring $864 million in aggregate debt principal to accelerate balance sheet deleveraging.

Segment Performance

• Medical Products & Therapies (MPT): Sales reached ~$2.1 billion (+6% reported and organic), supported by Infusion Systems, Drug Compounding, IV Solutions, and Advanced Surgery, partially offset by injectables.
• Healthcare Systems & Technologies (HST): Sales reached ~$806 million (+4% reported and organic), led by Care & Connectivity Solutions (Global Surgical Solutions and Patient Support Systems) and Front Line Care.

Raised Full-Year 2026 Outlook

• Reported Sales Growth: 4% to 5% (up from 3% to 4%).
• Organic Sales Growth: 3% to 4% (up from 2% to 3%).
• Adjusted Diluted EPS: $2.05 to $2.15 (narrowed/raised from prior range of $1.95 to $2.15).

Corporate Actions (Item 8.01)

• Dividend Declaration: The Board of Directors declared a quarterly cash dividend of $0.01 per share of common stock, payable January 4, 2027, to stockholders of record as of November 27, 2026.